Skip to Main Content
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
book

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

by Honghui Zhou, Diane R. Mould
March 2019
Intermediate to advanced content levelIntermediate to advanced
496 pages
15h
English
Wiley
Content preview from Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

18Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis – Peginterferon Beta‐1a, Daclizumab Beta, Natalizumab

Xiao Hu1,2Yaming Hang1,3Lei Diao1,4 Kumar K. Muralidharan1 and Ivan Nestorov1

1Biogen, 225 Binney Street, Cambridge, MA, 02142, USA

2Wave Life Sciences, 733 Concord Ave, Cambridge, MA, 02138, USA

3Takeda Pharmaceuticals International Co., Cambridge, MA, 02138, USA

4BMS China, 15F, Wheelock Square, 1717 West Nanjing Road, Shanghai, China

18.1 Introduction

Multiple sclerosis (MS) is an autoimmune inflammatory disorder of central nervous system (CNS), characterized by demyelination and variable degrees of axonal loss, resulting lesion sites in CNS. It affects approximately 400 000 people in the United States and 2.5 million worldwide and mostly young women (between ages 20 and 40 years) [14]. Based on clinical presentation, MS is categorized into three forms, relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), and primary progressive multiple sclerosis (PPMS). Both PPMS and SPMS are progressive forms of the disease and are generally more severe than RRMS. The clinical difference between PPMS and SPMS is that PPMS starts with progressive disease, while SPMS is developed from RRMS. RRMS is characterized by unpredictable relapses, followed by variable recovery and periods of clinical stability, and accounts for 80% of all MS patients. Within 10 years more than 50% of RRMS patients eventually ...

Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
and much more.
Start your free trial

You might also like

Applied Computing in Medicine and Health

Applied Computing in Medicine and Health

Dhiya Al-Jumeily, Abir Hussain, Conor Mallucci, Carol Oliver
Informatics for Health Professionals

Informatics for Health Professionals

Kathleen Mastrian, Dee McGonigle
Nanostructures for Novel Therapy

Nanostructures for Novel Therapy

Denisa Ficai, Alexandru Mihai Grumezescu

Publisher Resources

ISBN: 9781119289197Purchase book